Is there a drug interaction between Qelbree (viloxazine) and fluoxetine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, there is a clinically significant drug interaction between Qelbree (viloxazine) and fluoxetine that requires careful consideration.

Qelbree is a moderate CYP1A2 inhibitor, while fluoxetine is primarily metabolized by CYP2D6 and is itself a potent CYP2D6 inhibitor—the interaction risk is bidirectional but primarily concerns co-administration of Qelbree with other CYP1A2-sensitive substrates rather than fluoxetine specifically. However, the combination warrants caution due to overlapping serotonergic effects and the potential for additive side effects.

Primary Interaction Mechanism

The FDA label for Qelbree explicitly states that coadministration with moderate sensitive CYP1A2 substrates is not recommended, and dose reduction may be warranted 1. Viloxazine functions as a CYP1A2 inhibitor 2, which means it can increase plasma concentrations of drugs metabolized through this pathway.

Fluoxetine is NOT primarily metabolized by CYP1A2—it is metabolized through CYP2D6 3. Therefore, the direct pharmacokinetic interaction via CYP1A2 inhibition is minimal. However, fluoxetine itself is a potent CYP2D6 inhibitor and can dramatically increase levels of drugs metabolized by this enzyme (2-11 fold increases documented with tricyclics) 4.

Key Clinical Considerations

Viloxazine's Metabolic Profile

  • Viloxazine undergoes 5-hydroxylation via CYP2D6 as a minor pathway in humans 2
  • The estimated difference between poor metabolizers and extensive metabolizers is <2-fold, suggesting CYP2D6 inhibition by fluoxetine would have limited clinical impact on viloxazine levels 2
  • The major metabolic route is 5-hydroxylation followed by glucuronidation 2

Pharmacodynamic Concerns

The more significant concern is pharmacodynamic rather than pharmacokinetic:

  • Serotonergic effects: Viloxazine has serotonergic activity (5-HT2C agonism and 5-HT2B antagonism) 5, and fluoxetine is a selective serotonin reuptake inhibitor 3
  • Additive CNS effects: Both medications can cause somnolence, and viloxazine commonly causes sleepiness and tiredness 1
  • Suicidality monitoring: Both carry black box warnings for treatment-emergent suicidality, particularly in adolescents and young adults 3, 1

Common Pitfalls to Avoid

  1. Do not assume this is a contraindication: Unlike MAOIs (which are absolutely contraindicated with Qelbree 1), fluoxetine can potentially be used with viloxazine with appropriate monitoring

  2. Monitor for excessive sedation: The combination may produce additive CNS depression—counsel patients about driving and operating machinery 1

  3. Watch for cardiovascular effects: Both medications can affect blood pressure and heart rate; baseline and ongoing monitoring is essential 1

  4. Screen for bipolar disorder: Both medications can precipitate manic episodes in susceptible individuals 3, 1

Clinical Recommendation Algorithm

If considering this combination:

  • Start with lower doses of viloxazine when fluoxetine is already on board
  • Monitor closely for excessive somnolence, sedation, or fatigue
  • Check blood pressure and heart rate at baseline and during titration 1
  • Assess for mood destabilization or emergence of manic symptoms
  • Screen for suicidal ideation, especially in the first few months or with dose changes 1
  • Consider the clinical necessity—if ADHD symptoms are the primary target and depression is well-controlled on fluoxetine, the combination may be reasonable with monitoring

The interaction is manageable but not negligible—the primary concern is additive side effects rather than dangerous pharmacokinetic interactions. This differs substantially from the absolute contraindication with MAOIs or the "not recommended" status for CYP1A2 substrates like duloxetine, tizanidine, or theophylline 1.

Related Questions

Can I take Qulipta (viloxazine) together with Cymbalta (duloxetine)?
What are the dosing guidelines, contraindications, monitoring parameters, and common adverse effects of Qelbree (viloxazine) for ADHD?
In a 7‑year‑old female who develops abdominal pain and headache for about two weeks after atomoxetine dose adjustments and has tried all other ADHD medications except Qelbree (viloxazine), is Qelbree a suitable alternative?
What should be done for a 13-year-old who has been taking Qelbree (viloxazine) for four weeks without any improvement?
What are the differences between Strattera (atomoxetine) and Qelbree (viloxazine) regarding mechanism of action, dosing, side‑effect profile, and monitoring requirements?
What are the indications, dosing guidelines, and contraindications for glimepiride in adults with type 2 diabetes?
Should a patient with a normal lipid panel last year and no new cardiovascular risk factors repeat the test after one year?
Are the underwear free of viable mold spores and mycotoxins after washing at 60 °C with detergent and ironing?
Should a patient with hypothyroidism be treated with both liothyronine (T3) and levothyroxine (T4)?
In irritable bowel syndrome (IBS) refractory to dietary changes, what medication can be used to manage fluctuating bowel habits?
In a 48-year-old female with neurogenic bladder who currently has an indwelling Foley catheter that must be changed every two days because of leakage, should she continue the indwelling Foley or switch to clean intermittent (straight) catheterization every 4–6 hours?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.